1. Home
  2. PRE vs LCTX Comparison

PRE vs LCTX Comparison

Compare PRE & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

HOLD

Current Price

$17.91

Market Cap

303.5M

Sector

Industrials

ML Signal

HOLD

Logo Lineage Cell Therapeutics Inc.

LCTX

Lineage Cell Therapeutics Inc.

HOLD

Current Price

$1.14

Market Cap

301.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRE
LCTX
Founded
2014
1990
Country
Hong Kong
United States
Employees
98
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
303.5M
301.7M
IPO Year
N/A
1996

Fundamental Metrics

Financial Performance
Metric
PRE
LCTX
Price
$17.91
$1.14
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
4
Target Price
$30.50
$6.25
AVG Volume (30 Days)
232.2K
959.1K
Earning Date
06-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$14,556,000.00
Revenue This Year
$108.69
$109.40
Revenue Next Year
$58.68
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
53.24
52 Week Low
$7.18
$0.97
52 Week High
$23.63
$2.09

Technical Indicators

Market Signals
Indicator
PRE
LCTX
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
PRE
LCTX

About PRE Prenetics Global Limited

Prenetics Global Ltd is a consumer health and wellness company offering nutrition and longevity products through its flagship brand, IM8. It offers science-backed daily nutrition and longevity products distributed directly to consumers across multiple countries. The company's products are developed with scientific input and are subject to third-party quality certifications.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.

Share on Social Networks: